Randomization to Extend Stroke Intravenous ThromboLysis In Evolving Non-Large Vessel Occlusion With TNK (RESILIENT
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 466 participants.
Also called NCT05199662
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 466 participants
- Registry
-
NCT05199662
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Brazil
- Registry status
- Recruiting
Technical summary
Registry record NCT05199662. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-20 (actual); primary completion 2026-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomization to Extend Stroke Intravenous ThromboLysis In Evolving Non-Large Vessel Occlusion With TNK (RESILIENT
- Acronym
- EXTEND-IV
- Condition
- Ischemic Stroke, Acute
- Intervention (Drug)
- Intravenous tenecteplase
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hospital Moinhos de Vento
- Collaborator
- Ministry of Health, Brazil
- Collaborator
- Boehringer Ingelheim
- Collaborator
- Brainomix Limited
- Collaborator
- iSchemaView, Inc
Record details
- Record id
cardio:ct-nct05199662- Content hash
8e4861c4cfe027b11240775fe291312363d7b7a3df177c9041037d263669a123